Previous 10 | Next 10 |
Esperion Therapeutics (ESPR) announces the appointment of Sheldon Koenig as the company's president and chief executive officer, effective immediately.Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space, the company...
-- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO -- -- Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior ...
- Patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins and treated with NEXLETOL predicted to experience a 3.3% further absolute reduction in 10-year cardiovascular event risk compared with statins alone (p<0.0001) - - Patients considere...
Esperion recently reported their Q1 earnings that revealed a big miss on EPS and revenue. Consequently, the share price got cut ~30% as Street analyst cut their targets. Despite having impressive clinical data, NEXLETOL and NEXLIZET have had a disappointing launch thus far. However, t...
Esperion Therapeutics (NASDAQ: ESPR) widely missed on its first-quarter results. Those figures were published after market hours Tuesday, so the Wednesday fallout was ugly, with the company's stock closing 21.8% lower. In Q1 Esperion earned $8 million, over four times the $1.8 m...
Having lost more than a fifth of value so far, Esperion Therapeutics ([[ESPR]] -21.8%) is on course to mark its biggest one-day loss in nearly two years after its Q1 2021 results came below expectations.A downgrade by Stifel has added to the pressure with the analyst Derek Archila n...
Gainers: Regional Health Properties (RHE) +124%.SunLink Health Systems (SSY) +66%.Nemaura Medical (NMRD) +60%.Chiasma (CHMA) +48%.Athenex (ATNX) +31%.Caesarstone (CSTE) +30%.Hayward (HAYW) +28%.Altisource Portfolio Solutions (ASPS) +26%.Big 5 Sporting Goods (BGFV) +26%.American...
Esperion sheds nearly a third on Stifel cut Esperion Therapeutics (ESPR) has lost ~32.8% in the early hours after Stifel downgraded the stock to hold from buy noting “we don't think this story gets any better soon.”Esperion’s Q1 2021 financials came be...
Esperion Therapeutics (ESPR) -32% on Q1 earnings release.Cocrystal Pharma (COCP) -27% after launches $40M stock offering.SemiLEDs (LEDS) -21%.Mercury Systems (MRCY) -18% on FQ3 earnings release.Adamis Pharmaceuticals (ADMP) -14%.Reed's (REED) -14% after...
Esperion Therapeutics, Inc. (ESPR) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Benjamin Church - Head, Corporate Communications & IR Timothy Mayleben - President and Chief Executive Officer Sheldon Koenig - Chief Operating Officer Richard Bartram - Chief F...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...